Annexon presents vonaprument Phase 3 trial plans for geographic atrophy

Bitget2026/11/03 17:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Annexon remains on track for the 15-month primary analysis of its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in Q4 2026.
The trial enrolled 659 patients, with statistical power above 90% to assess vision protection.
Two predefined substudies supporting a US filing have 15-month analyses planned for Q1 2027; 24-month analyses are expected in Q3 2027.
Monthly vonaprument reduced the risk of confirmed vision loss of at least 15 letters by 73% versus sham in Phase 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Annexon presents vonaprument Phase 3 trial plans for geographic atrophy

You may also like

Crypto prices